Lifecare ASA

AGM Information • Dec 11, 2025

LIFECARE ASA: Extraordinary General Meeting

LIFECARE ASA: Extraordinary General Meeting

Lifecare ASA, a MedTech company developing next-generation continuous glucose

monitoring (CGM) technology, will hold an Extraordinary General Meeting on 2

January 2026 at 16:00 (CET).

Reference is made to earlier communication regarding the partially

underwritten rights issue of new shares with preferential rights for existing

shareholders, targeting total gross proceeds between NOK 80 million and NOK

100 million (the "Rights Issue").

An Extraordinary General Meeting will be held on 2 January 2026 to resolve the

following matters related to the Rights Issue:

* Share capital increase

* Issuance of Warrants Series 1 and Series 2

* Board authorization to issue shares as underwriting fee

* Issuance of Additional Warrants Series 1 and Series 2

The meeting will be conducted as a combined physical and digital meeting.

Shareholders who wish to participate and vote at the Extraordinary General

Meeting must be registered with a user profile in the meeting portal Orgbrain

(www.orgbrain.no (http://www.orgbrain.no/)). Attendance will be possible

either in person or digitally through Orgbrain.

The notice with the complete agenda and supporting documents is available

at https://lifecare.no/events/

(https://lifecare.no/investor/financial-calendar/).

About us

Lifecare ASA is a medical sensor company developing technology for sensing and

monitoring of various body analytes. Lifecare's focus is to bring the next

generation of Continuous Glucose Monitoring systems to market. Lifecare

enables osmotic pressure as sensing principle. Lifecare's sensor technology is

suitable for identifying and monitoring the occurrence of a wide range of

analytes and molecules in the human body and in pets.

Contacts

For further information, please contact:

Joacim Holter, CEO, joacim.holter@lifecare.no, +47 40 05 90 40

Renete Kaarvik, CFO, renete.kaarvik@lifecare.no, +47 94 83 82 42

This information is subject to disclosure under the Norwegian Securities

Trading Act, §5-12. The information was submitted for publication, through the

agency of the contact persons set out above, at 2025-12-11 15:00 CET.